Changchun Hi-Tech (000661.SZ): Clinical trial application for registration of domestically produced GenSci 136 drugs for injection approved

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registration of the domestically produced injectable GenSci 136 drug was approved. GenSci136 for injection is a BAFF/APRIL dual-target antagonist independently developed by Jinsai Pharmaceutical. It is classified as a class 1 therapeutic biological product in China and is intended to be used to treat systemic lupus erythematosus (SLE).